Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cystadenocarcinoma, Serous"" wg kryterium: Temat


Tytuł :
WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Autorzy :
Lee S; Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea.
Jun J; Division of Medical Genetics, University of California, San Diego, CA, U.S.A.
Kim WJ; Division of Medical Genetics, University of California, San Diego, CA, U.S.A.
Tamayo P; Division of Medical Genetics, University of California, San Diego, CA, U.S.A.
Howell SB; Division of Hematology, Department of Medicine, University of California, San Diego, CA, U.S.A. .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Nov; Vol. 40 (11), pp. 6017-6028.
Typ publikacji :
Journal Article
MeSH Terms :
Wnt Signaling Pathway*/genetics
Cystadenocarcinoma, Serous/*metabolism
Cystadenocarcinoma, Serous/*pathology
Ovarian Neoplasms/*metabolism
Ovarian Neoplasms/*pathology
Receptors, G-Protein-Coupled/*metabolism
Thrombospondins/*metabolism
Cystadenocarcinoma, Serous/genetics ; Fallopian Tubes/pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Intercellular Signaling Peptides and Proteins/genetics ; Intercellular Signaling Peptides and Proteins/metabolism ; Neoplasm Grading ; Ovarian Neoplasms/genetics ; Ovary/pathology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptors, G-Protein-Coupled/genetics ; Thrombospondins/genetics
Czasopismo naukowe
Tytuł :
GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
Autorzy :
El-Arabey AA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. .
Abdalla M; CAS Key Laboratory of Biofuels and Shandong Provincial Key Laboratory of Synthetic Biology, Qingdao Institute of Bioenergy and Bioprocess Technology Chinese Academy of Sciences, Qingdao, 266101, Shandong, China.
Abd-Allah AR; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Pokaż więcej
Źródło :
Human cell [Hum Cell] 2020 Jul; Vol. 33 (3), pp. 904-906. Date of Electronic Publication: 2020 May 09.
Typ publikacji :
Letter
MeSH Terms :
Cystadenocarcinoma, Serous/*genetics
Cystadenocarcinoma, Serous/*pathology
GATA3 Transcription Factor/*genetics
GATA3 Transcription Factor/*physiology
Neoplastic Stem Cells/*pathology
Ovarian Neoplasms/*genetics
Ovarian Neoplasms/*pathology
Cell Differentiation/genetics ; Cell Movement/genetics ; Cell Proliferation/genetics ; Cystadenocarcinoma, Serous/diagnosis ; Cystadenocarcinoma, Serous/therapy ; Female ; Gene Expression ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Molecular Targeted Therapy ; Neoplasm Staging ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/therapy ; Protein-Serine-Threonine Kinases/genetics ; Protein-Serine-Threonine Kinases/metabolism
Opinia redakcyjna
Tytuł :
Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
Autorzy :
Mittempergher L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Piskorz AM; Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom.
Bosma AJ; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michaut M; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Wisman GBA; Department of Gynecologic Oncology, Cancer Research Center Groningen, University of Groningen, Groningen, The Netherlands.
Kluin RJC; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nieuwland M; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Brugman W; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Ven KJW; Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Marass F; Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom.; Department of Biosystems Science and Engineering and Swiss Institute of Bioinformatics, ETH Zurich, Basel, Switzerland.
Morris J; Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom.
Rosenfeld N; Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom.
Jimenez-Linan M; Cancer Research UK Major Centre-Cambridge, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
de Jong S; Department of Medical Oncology, Cancer Research Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
van der Zee AGJ; Department of Gynecologic Oncology, Cancer Research Center Groningen, University of Groningen, Groningen, The Netherlands.
Brenton JD; Cancer Research UK Cambridge Institute University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom.
Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jul 08; Vol. 15 (7), pp. e0235766. Date of Electronic Publication: 2020 Jul 08 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
BRCA1 Protein/*genetics
Cystadenocarcinoma, Serous/*genetics
Janus Kinase 3/*genetics
Ovarian Neoplasms/*genetics
Protein Kinases/*genetics
Tumor Suppressor Protein p53/*genetics
BRCA1 Protein/metabolism ; Case-Control Studies ; Cohort Studies ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Janus Kinase 3/metabolism ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Protein Kinases/metabolism ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł :
Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.
Autorzy :
Varankar SS; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
More M; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Abraham A; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Pansare K; Institute for Plasma Research & Tata Memorial Centre, Kharghar, Navi-Mumbai, India.
Kumar B; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Narayanan NJ; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Jolly MK; Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.
Mali AM; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Bapat SA; National Centre for Cell Science, Savitribai Phule Pune University, Ganeshkhind, Pune, India.
Pokaż więcej
Źródło :
Carcinogenesis [Carcinogenesis] 2020 Jun 17; Vol. 41 (4), pp. 515-526.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Movement*
Cell Plasticity*
Gene Expression Regulation, Neoplastic*
Basic Helix-Loop-Helix Transcription Factors/*metabolism
Cystadenocarcinoma, Serous/*pathology
Ovarian Neoplasms/*pathology
Snail Family Transcription Factors/*metabolism
Basic Helix-Loop-Helix Transcription Factors/genetics ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/metabolism ; Epithelial-Mesenchymal Transition ; Female ; Humans ; Neoplasm Grading ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Snail Family Transcription Factors/genetics ; Tumor Cells, Cultured ; Tumor Microenvironment ; Wound Healing
Czasopismo naukowe
Tytuł :
In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
Autorzy :
Kim O; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Park EY; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Klinkebiel DL; Department of Biochemistry and Molecular Biology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Pack SD; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Shin YH; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Abdullaev Z; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Emerson RE; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Coffey DM; Department of Pathology and Genomic Medicine, Houston Methodist and Weill Cornell Medical College, Houston, Texas, United States of America.
Kwon SY; Department of Pathology, School of Medicine, Keimyung University, Daegu, Republic of Korea.
Creighton CJ; Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Kwon S; Research and Development Center, Bioway Inc, Seoul, Republic of Korea.
Chang EC; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, United States of America.
Chiang T; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, United States of America.
Yatsenko AN; Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Chien J; Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, California, United States of America.
Cheon DJ; Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, NY, United States of America.
Yang-Hartwich Y; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, United States of America.
Nakshatri H; Department of Surgery, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Nephew KP; Medical Sciences Program, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Bloomington, Indiana, United States of America.
Behringer RR; Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Fernández FM; School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Cho CH; Department of Obstetrics and Gynecology, School of Medicine, Keimyung University, Daegu, Republic of Korea.
Vanderhyden B; Department of Cellular and Molecular Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Drapkin R; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Bast RC Jr; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Miller KD; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine Indianapolis, Indiana, United States of America.
Karpf AR; Eppley Institute for Cancer Research, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Kim J; Department of Biochemistry and Molecular Biology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Pokaż więcej
Źródło :
PLoS genetics [PLoS Genet] 2020 Jun 04; Vol. 16 (6), pp. e1008808. Date of Electronic Publication: 2020 Jun 04 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Cystadenocarcinoma, Serous/*genetics
Ovarian Neoplasms/*pathology
Peritoneal Neoplasms/*genetics
Animals ; Antineoplastic Agents/therapeutic use ; Cell Line, Tumor ; Chromosomal Instability ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/secondary ; DEAD-box RNA Helicases/genetics ; DNA Repair ; Disease Models, Animal ; Drug Resistance, Neoplasm/genetics ; Drug Screening Assays, Antitumor/methods ; Feasibility Studies ; Female ; Humans ; Mice ; Mice, Knockout ; Mutation ; Neoplasm Grading ; Neoplasm Metastasis/genetics ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; PTEN Phosphohydrolase/genetics ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/secondary ; Primary Cell Culture ; Ribonuclease III/genetics ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Tytuł :
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Autorzy :
Jiménez-Sánchez A; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.; Department of Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cybulska P; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mager KL; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Koplev S; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Cast O; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Couturier DL; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Memon D; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikolovski I; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mazaheri Y; Department of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
Bykov Y; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Geyer FC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Macintyre G; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.; Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Gavarró LM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Drews RM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Gill MB; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Papanastasiou AD; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sosa RE; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Soslow RA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Walther T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chi DS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Park KJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hollmann T; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Markowetz F; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Beltrao P; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Vargas HA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zamarin D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Snyder A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sala E; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Radiology and Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Miller ML; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK. .
Pokaż więcej
Źródło :
Nature genetics [Nat Genet] 2020 Jun; Vol. 52 (6), pp. 582-593. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Gene Expression Regulation, Neoplastic*/drug effects
Cystadenocarcinoma, Serous/*drug therapy
Ovarian Neoplasms/*drug therapy
Tumor Microenvironment/*immunology
Animals ; Cisplatin/immunology ; Cisplatin/pharmacology ; Cohort Studies ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/immunology ; DNA Copy Number Variations ; Female ; Gene Expression Profiling/statistics & numerical data ; Genes, myc ; Humans ; Killer Cells, Natural/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/pathology ; Mice ; Mutation ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/immunology ; Principal Component Analysis ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/genetics ; Wnt Signaling Pathway
Czasopismo naukowe
Tytuł :
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Autorzy :
Konstantinopoulos PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: .
Cheng SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wahner Hendrickson AE; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Penson RT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Schumer ST; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Doyle LA; Department of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Lee EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kohn EC; Department of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Duska LR; Department of Obstetrics and Gynecology, Cancer Center, University of Virginia, Charlottesville, VA, USA.
Crispens MA; Department of Obstetrics and Gynecology, Ingram Cancer Center, Vanderbilt University Nashville, TN, USA.
Olawaiye AB; Department of Obstetrics and Gynecology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Winer IS; Department of Obstetrics and Gynecology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Barroilhet LM; Department of Obstetrics and Gynecology, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
Fu S; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA.
McHale MT; Department of Obstetrics and Gynecology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Schilder RJ; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Färkkilä A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chowdhury D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Curtis J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Quinn RS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bowes B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
D'Andrea AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Jul; Vol. 21 (7), pp. 957-968. Date of Electronic Publication: 2020 Jun 15.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Drug Resistance, Neoplasm/*drug effects
Ovarian Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cystadenocarcinoma, Serous/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Follow-Up Studies ; Humans ; Isoxazoles/administration & dosage ; Middle Aged ; Neoplasm Grading ; Ovarian Neoplasms/pathology ; Platinum/pharmacology ; Pyrazines/administration & dosage ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł :
Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation.
Autorzy :
Ono T; Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Kishimoto K; Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Tajima S; Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.
Maeda I; Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.
Takagi M; Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.
Suzuki N; Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan.
Mimura H; Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Pokaż więcej
Źródło :
Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] 2020 Jul; Vol. 61 (7), pp. 992-1000. Date of Electronic Publication: 2019 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma, Clear Cell/*diagnostic imaging
Carcinoma, Endometrioid/*diagnostic imaging
Cystadenocarcinoma, Serous/*diagnostic imaging
Diffusion Magnetic Resonance Imaging/*methods
Ovarian Neoplasms/*diagnostic imaging
Adenocarcinoma, Clear Cell/pathology ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Endometrioid/pathology ; Cystadenocarcinoma, Serous/pathology ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Ovarian Neoplasms/pathology ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Autorzy :
Price JC; Integrated Program in Cellular Molecular and Biomedical Studies, Columbia University, New York, NY, United States of America.
Azizi E; Program for Computational and Systems Biology, Parker Institute for Cancer Immunotherapy, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Naiche LA; Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, United States of America.
Parvani JG; Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, United States of America.
Shukla P; Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, United States of America.
Kim S; Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, United States of America.
Slack-Davis JK; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, United States of America.
Pe'er D; Program for Computational and Systems Biology, Parker Institute for Cancer Immunotherapy, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Kitajewski JK; Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jun 11; Vol. 15 (6), pp. e0233962. Date of Electronic Publication: 2020 Jun 11 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Ovarian Epithelial/*secondary
Cystadenocarcinoma, Serous/*secondary
Ovarian Neoplasms/*pathology
Peritoneal Neoplasms/*secondary
Receptor, Notch3/*metabolism
Animals ; Carcinogenesis/metabolism ; Carcinoma, Ovarian Epithelial/metabolism ; Cell Adhesion ; Cell Line, Tumor ; Cystadenocarcinoma, Serous/metabolism ; Disease Progression ; Extracellular Matrix Proteins/metabolism ; Female ; Humans ; Mice ; Mice, Nude ; Ovarian Neoplasms/metabolism ; Peritoneal Neoplasms/metabolism ; Receptor, Notch3/genetics
Czasopismo naukowe
Tytuł :
Disparities in care among patients with low-grade serous ovarian carcinoma.
Autorzy :
Siemon J; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States. Electronic address: .
Galli J; University of Miami Ryan White Program, Miami, FL, United States.
Slomovitz B; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
Schlumbrecht M; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Apr; Vol. 157 (1), pp. 46-54. Date of Electronic Publication: 2020 Jan 31.
Typ publikacji :
Journal Article
MeSH Terms :
Cystadenocarcinoma, Serous/*ethnology
Cystadenocarcinoma, Serous/*therapy
Healthcare Disparities/*ethnology
Ovarian Neoplasms/*ethnology
Ovarian Neoplasms/*therapy
Adolescent ; Adult ; African Continental Ancestry Group/statistics & numerical data ; Aged ; Aged, 80 and over ; Cystadenocarcinoma, Serous/economics ; Cystadenocarcinoma, Serous/pathology ; European Continental Ancestry Group/statistics & numerical data ; Female ; Healthcare Disparities/economics ; Healthcare Disparities/statistics & numerical data ; Hispanic Americans/statistics & numerical data ; Humans ; Insurance Coverage ; Middle Aged ; National Health Programs ; Ovarian Neoplasms/economics ; Ovarian Neoplasms/pathology ; Survival Rate ; United States/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Autorzy :
Siamakpour-Reihani S; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, United States. Electronic address: .
Cobb LP; Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, United States.
Jiang C; Bioinformatics Shared Resource, Duke Cancer Institute, United States. Electronic address: .
Zhang D; Bioinformatics Shared Resource, Duke Cancer Institute, United States. Electronic address: .
Previs RA; Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: .
Owzar K; Duke Department of Biostatistics and Bioinformatics, Duke University Medical Center, United States; Bioinformatics Shared Resource, Duke Cancer Institute, United States. Electronic address: .
Nixon AB; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, United States. Electronic address: .
Alvarez Secord A; Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: .
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 662-668. Date of Electronic Publication: 2020 Jan 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cystadenocarcinoma, Serous/*genetics
Cystadenocarcinoma, Serous/*immunology
Ovarian Neoplasms/*genetics
Ovarian Neoplasms/*immunology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/genetics ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/immunology ; Carcinoma, Ovarian Epithelial/surgery ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/surgery ; Databases, Genetic ; Female ; Gene Expression ; Humans ; Middle Aged ; Neoplasm Grading ; Oligonucleotide Array Sequence Analysis ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/surgery ; Receptors, Interleukin-6/biosynthesis ; Receptors, Interleukin-6/genetics ; Receptors, Interleukin-6/immunology ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Low-grade serous ovarian cancer: State of the science.
Autorzy :
Slomovitz B; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States. Electronic address: .
Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, UK.
Carey MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Malpica A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Shih IM; Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Huntsman D; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Fader AN; Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Grisham RN; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weil Cornell Medical College, New York, NY, United States.
Schlumbrecht M; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.
Sun CC; Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ludemann J; Cure Our Ovarian Cancer, cureourovariancancer.org, New Zealand.
Cooney GA; University of Miami/JFK Medical Center Palm Beach Regional Graduate Medical Education Consortium, Hospice and Palliative Medicine Program, West Palm Beach, FL, United States.
Coleman R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Mahdi H; Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, OH, United States; Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States.
Wong KK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Covens A; University of Toronto, Division of Gynecologic Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
O'Malley DM; Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, The James CCC at the Wexner Medical Center-The Ohio State University College of Medicine, Columbus, OH, United States.
Lecuru F; Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen George Pompidou, APHP, Paris, France; Faculté de Médecine, Université Paris Descartes, Paris, France.
Cobb LP; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Caputo TA; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, United States.
May T; Division of Gynecologic Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Huang M; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.
Siemon J; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.
Fernández ML; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
Ray-Coquard I; Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire (GINECO), Lyon, France.
Gershenson DM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 715-725. Date of Electronic Publication: 2020 Jan 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cystadenocarcinoma, Serous/*diagnosis
Cystadenocarcinoma, Serous/*therapy
Ovarian Neoplasms/*diagnosis
Ovarian Neoplasms/*therapy
Animals ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Female ; Humans ; MAP Kinase Signaling System ; Neoplasm Invasiveness ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Autorzy :
Sanij E; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. .; Department of Clinical Pathology, University of Melbourne, Parkville, VIC, 3010, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia. .
Hannan KM; ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Acton, 2601, Australia Capital Territory, Australia. .; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia. .
Xuan J; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Yan S; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Ahern JE; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Trigos AS; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Brajanovski N; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Son J; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Chan KT; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Kondrashova O; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, 3010, Australia.
Lieschke E; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.
Wakefield MJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.; Melbourne Bioinformatics, University of Melbourne, Victoria, 3010, Australia.
Frank D; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, 3010, Australia.
Ellis S; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Cullinane C; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Kang J; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.
Poortinga G; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, VIC, 3010, Australia.
Nag P; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.; School of Environment and Sciences, Griffith University, Nathan, Brisbane, QLD, 4111, Australia.
Deans AJ; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, VIC, 3010, Australia.; Genome Stability Unit, St Vincent's Institute, Fitzroy, VIC, 3065, Australia.
Khanna KK; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Mileshkin L; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
McArthur GA; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, VIC, 3010, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, VIC, 3010, Australia.
Soong J; Senhwa Biosciences, Virginia Commonwealth University School of Medicine, San Diego, CA, USA.
Berns EMJJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Hannan RD; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.; ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Acton, 2601, Australia Capital Territory, Australia.; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia.; School of Biomedical Sciences, University of Queensland, Brisbane, QLD, 4072, Australia.
Scott CL; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.; Department of Medicine and Health Sciences, Monash University, Clayton, VIC, 3168, Australia.
Sheppard KE; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia.
Pearson RB; Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC, 3000, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia. .; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, VIC, 3010, Australia. .; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 May 26; Vol. 11 (1), pp. 2641. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Damage*
Benzothiazoles/*pharmacology
Cystadenocarcinoma, Serous/*drug therapy
Naphthyridines/*pharmacology
Ovarian Neoplasms/*drug therapy
Animals ; Cell Line, Tumor ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/metabolism ; DNA Replication/drug effects ; Drug Resistance, Neoplasm ; Enzyme Inhibitors/pharmacology ; Female ; Heterografts ; Homologous Recombination ; Humans ; Mice ; Mice, Inbred NOD ; Mice, Knockout ; Mice, SCID ; Models, Biological ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; RNA Polymerase I/antagonists & inhibitors ; Transcriptome
Czasopismo naukowe
Tytuł :
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Autorzy :
Tran LKH; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Tran PMH; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Mysona DP; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Purohit SB; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA; Department of Undergraduate Health Professionals, College of Allied Health Sciences, Augusta University, 1120 15(th) Street, Augusta, GA 30912, USA.
Myers E; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Lee WS; Department of Pathology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Dun B; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Xu D; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Liu H; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Hopkins D; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Nechtman J; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA.
Scelsi CL; Department of Radiology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Mittal PK; Department of Radiology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Kleven D; Department of Pathology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Wallbillich JJ; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Rungruang B; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
Ghamande S; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA.
She JX; Center for Biotechnology and Genomic Medicine, 1120 15(th) Street, Augusta, GA 30912, USA; Department of Obstetrics and Gynecology, Medical College of Georgia, 1120 15(th) Street, Augusta, GA 30912, USA. Electronic address: .
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 May; Vol. 157 (2), pp. 340-347. Date of Electronic Publication: 2020 Feb 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cystadenocarcinoma, Serous/*genetics
Uterine Neoplasms/*genetics
Aged ; Aged, 80 and over ; Cohort Studies ; Cystadenocarcinoma, Serous/mortality ; Cystadenocarcinoma, Serous/pathology ; Cystadenocarcinoma, Serous/therapy ; Disease Progression ; Female ; Humans ; Middle Aged ; Prognosis ; Reproducibility of Results ; Retrospective Studies ; Sequence Analysis, RNA ; Tissue Array Analysis ; Transcriptome ; Tumor Cells, Cultured ; Uterine Neoplasms/mortality ; Uterine Neoplasms/pathology ; Uterine Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Autorzy :
Sun L; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen.
Yang M; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen.
Zhang X; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen.
Li H; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen.
Wu L; Departments of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Zhang Y; The Medical Department, 3D Medicines Inc, Shanghai, People's Republic of China.
Cai S; The Medical Department, 3D Medicines Inc, Shanghai, People's Republic of China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May; Vol. 99 (20), pp. e20053.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Cystadenocarcinoma, Serous/*drug therapy
Etoposide/*therapeutic use
Indoles/*therapeutic use
Ovarian Neoplasms/*drug therapy
Quinolines/*therapeutic use
Administration, Oral ; Antineoplastic Combined Chemotherapy Protocols ; Cystadenocarcinoma, Serous/diagnostic imaging ; Cystadenocarcinoma, Serous/surgery ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/diagnostic imaging ; Ovarian Neoplasms/surgery
Czasopismo naukowe
Tytuł :
Inhibition of miR-141 and miR-200a Increase DLC-1 and ZEB2 Expression, Enhance Migration and Invasion in Metastatic Serous Ovarian Cancer.
Autorzy :
Wahab NA; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Othman Z; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Nasri NWM; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Mokhtar MH; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Ibrahim SF; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Hamid AA; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Raja Ali RA; Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Mokhtar NM; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
Pokaż więcej
Źródło :
International journal of environmental research and public health [Int J Environ Res Public Health] 2020 Apr 17; Vol. 17 (8). Date of Electronic Publication: 2020 Apr 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Ovarian Epithelial*/metabolism
Carcinoma, Ovarian Epithelial*/pathology
Cystadenocarcinoma, Serous*/metabolism
Cystadenocarcinoma, Serous*/pathology
GTPase-Activating Proteins*/metabolism
MicroRNAs*/metabolism
Ovarian Neoplasms*/metabolism
Ovarian Neoplasms*/pathology
Tumor Suppressor Proteins*/metabolism
Zinc Finger E-box Binding Homeobox 2*/metabolism
Cell Line, Tumor ; Cell Movement ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł :
Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Autorzy :
Lee YJ; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim D; Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Shim JE; Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Bae SJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim S; Department of Biomedical Systems Informatics, Bran Korea 21 PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee H; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim SH; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jo SB; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim HS; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Paik S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2020 Apr 01; Vol. 146 (7), pp. 1851-1861. Date of Electronic Publication: 2019 Nov 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Cystadenocarcinoma, Serous/*genetics
Ovarian Neoplasms/*genetics
Ovary/*pathology
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Cell Cycle/genetics ; Cystadenocarcinoma, Serous/mortality ; Cystadenocarcinoma, Serous/therapy ; Cytoreduction Surgical Procedures/methods ; Disease Progression ; Drug Resistance, Neoplasm/genetics ; Female ; Genomics ; Humans ; Middle Aged ; Mutation/drug effects ; Neoadjuvant Therapy/methods ; Neoplasm, Residual ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/therapy ; Ovariectomy/methods ; Ovary/drug effects ; Phosphatidylinositol 3-Kinases/metabolism ; Progression-Free Survival ; Proto-Oncogene Proteins c-akt/metabolism ; Retrospective Studies ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Survival Analysis ; TOR Serine-Threonine Kinases/metabolism
Czasopismo naukowe
Tytuł :
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Autorzy :
Llaurado Fernandez M; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Dawson A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Kim H; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Lam N; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Russell H; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Bruce M; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Bittner M; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Hoenisch J; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Scott SA; Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: .
Talhouk A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Chiu D; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Provencher D; Division of Gynecologic-Oncology, Centre Hospitalier de l'Université de Montréal (CHUM) and Centre de Recherche du CHUM, Montreal, Quebec, Canada. Electronic address: .
Nourmoussavi M; Division of Gynecologic-Oncology, Centre Hospitalier de l'Université de Montréal (CHUM) and Centre de Recherche du CHUM, Montreal, Quebec, Canada.
DiMattia G; Department of Oncology, University of Western Ontario, London, Ontario, Canada. Electronic address: .
Lee CH; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Gilks CB; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Alberta Public Lab, Calgary, Alberta, Canada. Electronic address: .
Carey MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Apr; Vol. 157 (1), pp. 12-20. Date of Electronic Publication: 2020 Jan 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cystadenocarcinoma, Serous/*metabolism
Ovarian Neoplasms/*metabolism
Receptors, Estrogen/*biosynthesis
Receptors, Progesterone/*biosynthesis
Biomarkers, Tumor/biosynthesis ; Cell Line, Tumor ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/pathology ; Disease Progression ; Estradiol/pharmacology ; Estrogen Antagonists/pharmacology ; Female ; Hep G2 Cells ; Humans ; Immunohistochemistry ; MCF-7 Cells ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Prognosis ; Receptors, Estrogen/antagonists & inhibitors ; Tamoxifen/pharmacology ; Tissue Array Analysis
Czasopismo naukowe
Tytuł :
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Autorzy :
Scott SA; Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: .
Llaurado Fernandez M; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Kim H; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Elit L; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.
Nourmoussavi M; Division of Gynecologic-Oncology, Centre Hospitalier de Université de Montréal, (CHUM) and Centre de recherche du CHUM, Montreal, Quebec, Canada.
Glaze S; Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada.
Roberts L; Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova Scotia, Canada.
Offman SL; Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova Scotia, Canada.
Rahimi K; Department of Pathology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Lytwyn A; Department of Pathology and Molecular Medicine, Health Research Methods, Evaluation, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
Sur M; Department of Pathology and Molecular Medicine, McMaster University and The Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada.
Gilks CB; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Matheson K; Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova Scotia, Canada.
Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Dawson A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Tinker AV; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Kwon JS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Hoskins P; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Santos JL; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Cheung A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Provencher D; Division of Gynecologic-Oncology, Centre Hospitalier de Université de Montréal, (CHUM) and Centre de recherche du CHUM, Montreal, Quebec, Canada.
Carey MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Pokaż więcej
Corporate Authors :
Canadian LGSC Community of Practice (GOC-CoP)
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Apr; Vol. 157 (1), pp. 36-45. Date of Electronic Publication: 2020 Jan 27.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Practice Patterns, Physicians'*
Cystadenocarcinoma, Serous/*drug therapy
Cystadenocarcinoma, Serous/*surgery
Ovarian Neoplasms/*drug therapy
Ovarian Neoplasms/*surgery
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carboplatin/administration & dosage ; Cisplatin/administration & dosage ; Cohort Studies ; Cystadenocarcinoma, Serous/pathology ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Progression-Free Survival ; Retrospective Studies ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[A case of systemic sclerosis].
Autorzy :
Taieb D; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France.
Chauveau S; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France.
Khamis W; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France.
de Montmollin N; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France.
Sesé L; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France.
Duchemann B; Service d'oncologie, hôpital Avicenne, AP-HP, Bobigny, France.
Nunes H; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France; Inserm UMR 1272, laboratoire « hypoxie et poumon », université Paris 13, Bobigny, France.
Uzunhan Y; Service de pneumologie, hôpital Avicenne, centre de référence des maladies pulmonaires rares de l'adulte, site constitutif, AP-HP, 125, rue de Stalingrad, 93000 Bobigny, France; Inserm UMR 1272, laboratoire « hypoxie et poumon », université Paris 13, Bobigny, France. Electronic address: .
Pokaż więcej
Transliterated Title :
U ne rémission « en peau de chagrin ».
Źródło :
Revue des maladies respiratoires [Rev Mal Respir] 2020 Apr; Vol. 37 (4), pp. 341-345. Date of Electronic Publication: 2020 Apr 10.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Cystadenocarcinoma, Serous/*complications
Flecainide/*adverse effects
Lung Diseases, Interstitial/*chemically induced
Ovarian Neoplasms/*complications
Scleroderma, Systemic/*complications
Scleroderma, Systemic/*diagnosis
Aged ; Autoantibodies/blood ; Cystadenocarcinoma, Serous/pathology ; Cystadenocarcinoma, Serous/therapy ; Female ; Humans ; Lung Diseases, Interstitial/complications ; Lung Diseases, Interstitial/immunology ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; RNA Polymerase III/immunology ; Remission Induction ; Scleroderma, Systemic/blood
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies